New Clinical Data on AC Immune’s Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PDTM Conference
Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose
and monitor tauopathies, including AD and PSP
New data further support 18F-PI-2620’s potential as a new PET Tracer for
progressive supranuclear palsy (PSP) detection
AC Immune SA, a Swiss- based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Life Molecular Imaging (LMI, formerly Piramal Imaging) together with its collaboration partners will present new data on 18F-PI- 2620, a novel next generation investigational Tau PET-tracer, at the 14th International
Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM), taking place March 26th- 31st in Lisbon.